BPGbio Brings Late Clinical Stage Rare Disease and Oncology Assets to US and EU Pharma Partnering Summits
BPGbio’s executives, including Daniel Elliott , Board Member and Chief Commercial Advisor, plan to share details of the company’s commercial ready assets.
- BPGbio’s executives, including Daniel Elliott , Board Member and Chief Commercial Advisor, plan to share details of the company’s commercial ready assets.
- BPM31510 acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death.
- BPGbio is also exploring a late stage trial with BPM31510-IV/oral for primary coenzyme Q10 deficiency , an ultra-rare, potentially life threatening disease that affects the brain, muscles, and kidneys in afflicted patients.
- This platform identifies targets, biomarkers, and drugs and assists the development team through both the development and clinical trial stages.